Latest study shows Enhertu, rejected by Nice, can stall growth of tumours by a year, longer than standard chemotherapy
Thousands of women with advanced breast cancer in England and Wales are being denied a drug that cuts the risk of the disease spreading by more than a third.
Enhertu has been rolled out to patients with HER2-low breast cancer in Scotland and Northern Ireland, but the National Institute for Health and Care Excellence (Nice) has rejected it for patients in England. Women in Wales are also being denied the drug.
About Author
More Stories
Newborns treated with antibiotics respond less well to vaccines, study shows
As a geneticist, I will not mourn 23andMe and its jumble of useless health information | Adam Rutherford
Are rising lower respiratory infection hospital admissions linked to dirty air?